Stage III EGFR Lung Cancer: Roxanne's Patient Story

Patient Info: Roxanne, Female, 40s | Stage III

Biomarkers: EGFR mutation

Roxanne had Stage III EGFR-mutated lung cancer after surgery found mediastinal lymph-node involvement. As of March 2026, she was living with the long-term effects of surgery, chemotherapy, radiation, and ongoing EGFR-targeted therapy, while also managing the emotional and financial burden of cancer as a single parent.

The Patient StoryRead more →

Stage III HER2-Positive Inflammatory Breast Cancer: Rebecca's Survivor Story

Patient Info: Rebecca, Female | Stage III

Biomarkers: HER2-positive; hormone receptor-negative

Rebecca was entering her 6th year of remission after Stage IIIC HER2-positive, hormone receptor-negative inflammatory breast cancer, while continuing to manage recurrence fears and annual scares.

The Patient StoryRead more →

Targeted therapy made Stage III ALK-positive lung cancer operable

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: ALK-positive; PD-L1 high

Surgery found no residual cancer, and follow-up scans showed no recurrence through 15 months.

PubMed CentralRead more →

Stage III Colorectal Cancer: Amber's Survivor Story

Patient Info: Amber Mike, Female, 40s | Stage III

As of February 2026, Amber had completed Stage III colorectal cancer treatment, was doing well under close monitoring with tumor markers every 3 months, and was rebuilding life through survivorship, therapy, travel, and advocacy.

City of HopeRead more →

Recovery from severe liver injury during Stage III gastric cancer treatment

Patient Info: Anonymized, Male, 70+ | Stage III

At the last follow-up in August 2025, imaging showed no recurrence and his liver function remained normal.

PubMed CentralRead more →

Stage III Colorectal Cancer: John's Survivor Story

Patient Info: John Murray, Male, 50s | Stage III

As of February 2026, John’s latest tests showed no evidence of cancer after Stage III rectal cancer treatment, including chemotherapy, radiation, and laparoscopic surgery with permanent colostomy; close surveillance was planned for 2 years.

Cleveland ClinicRead more →

Stage III HER2-Positive Breast Cancer: Caroline's Patient Story

Patient Info: Caroline McNally, Female, Under 40 | Stage III

Biomarkers: Hormone-positive component reported; exact ER/PR/HER2 panel not stated

As of February 2026, Caroline was in active treatment for Stage III hormone-positive breast cancer, receiving Taxol after dose-dense AC and preparing for double mastectomy, likely radiation, and hormone therapy.

Stage IIIB triple-negative metaplastic breast cancer: urgent mastectomy and reconstruction after rapid progression on neoadjuvant therapy

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; nuclear grade 3

At 18-month follow-up, she was disease-free after urgent mastectomy, axillary dissection, flap/skin-graft reconstruction, resumed chemotherapy, and radiation for rapidly progressive triple-negative metaplastic breast cancer.

PubMed CentralRead more →

Stage III Breast Cancer Treatment Complicated by Coronary Thrombosis

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 25–30%

She achieved complete remission about 12 months after the myocardial infarction and remained in complete oncologic remission at 44 months.

PubMed CentralRead more →

Stage 3 triple-negative breast cancer complicated by immunotherapy endocrine toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PgR-negative/PR-negative; HER2 0; Ki-67 70%; triple-negative breast cancer

After neoadjuvant therapy complicated by immune-related hypothyroidism, adrenal insufficiency, and suspected hypophysitis, surgery showed residual ypT1c ypN0 triple-negative disease. Pembrolizumab was stopped, adjuvant capecitabine was completed in June 2025, and endocrine replacement/follow-up continued.

PubMed CentralRead more →

Stage III Ovarian Cancer: Angela's Patient Story

Patient Info: Angela Hernandez, female, Under 40 | Stage III

Angela Hernandez was 32 when persistent bloating and a hard area found during a well-woman exam led to a Stage III ovarian cancer diagnosis.

MD AndersonRead more →

Stage III Ovarian Cancer: Carla's Patient Story

Patient Info: Carla Peoples, female, 60s | Stage III

Carla Peoples was 65 when months of increasingly severe abdominal bloating and hardening led to a Stage III ovarian cancer diagnosis.

MD AndersonRead more →

Stage III Colorectal Cancer: Briana's Survivor Story

Patient Info: Briana, Female, Under 40 | Stage III

A CT scan before completion of chemotherapy showed no signs of disease; she later had colostomy reversal and returned to work and normal activity while continuing scan surveillance.

The Patient StoryRead more →

Stage IIIA KRAS/STK11/TP53-mutated lung adenocarcinoma: fatal pembrolizumab-induced myocarditis after adjuvant therapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Ki-67 20-25%; PD-L1 expression 10%; KRAS exon 2 mutation; STK11 mutation; TP53 mutation

As of December 2025, he had died after 15 days of hospitalization from sepsis and multi-organ failure following severe pembrolizumab-induced myocarditis after adjuvant treatment for resected Stage IIIA lung adenocarcinoma.

PubMed CentralRead more →

Ovarian Cancer Remission With Olaparib After Chemotherapy Intolerance

Patient Info: Anonymized, female, 50s | Stage III

Biomarkers: germline BRCA1 mutation

At 48 months, imaging showed complete remission and CA125 was normal while she continued reduced-dose olaparib.

PubMed CentralRead more →

Stage III MSI-High Colorectal Cancer: Tommy's Survivor Story

Patient Info: Tommy Allen, Male, 50s | Stage III

Biomarkers: MSI-high; Lynch syndrome

As of November 2025, Tommy was cancer-free 5 years after pembrolizumab, ileostomy, Whipple procedure, partial colectomy, and ileostomy closure for Stage III MSI-high colon cancer with Lynch syndrome.

MD AndersonRead more →

Teenage colorectal cancer: Stage III signet-ring adenocarcinoma and 10-year disease-free follow-up after FOLFOX

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: CDX2-positive; CK7-positive; AE1-AE3-positive; signet-ring cell adenocarcinoma histology

As of November 2025, she was disease-free 10 years after laparoscopic right hemicolectomy with clear margins and 6 months of adjuvant FOLFOX for T4N2Mx signet-ring colon adenocarcinoma.

PubMed CentralRead more →

Young Woman With Rare Small Cell Ovarian Cancer and Abdominal Recurrence

Patient Info: Anonymized, female, Under 40 | Stage III

Biomarkers: loss of SMARCA4 expression; retained SMARCB1 expression

The recurrent cancer continued to progress despite further chemotherapy, and she died at home 26 months after the initial diagnosis.

PubMed CentralRead more →

Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

Stage III Invasive Lobular Carcinoma: Stacy's Survivor Story

Patient Info: Stacy, Female | Stage III

Biomarkers: Hormone receptor-positive; HER2-negative

Stacy completed chemotherapy, mastectomy, radiation and reconstruction. She remained under regular monitoring and was taking Letrozole as part of a planned 10-year course.

Lobular Breast Cancer AllianceRead more →

Stage IIIB RET-fusion lung adenocarcinoma: disease-free after pralsetinib, surgery and maintenance therapy

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: RET exon 12 fusion. Lung-origin markers were present

After neoadjuvant pralsetinib, surgery showed pathological complete response with negative lymph nodes. As of 16 April 2025, surveillance imaging showed no recurrence while he remained on pralsetinib 300 mg once daily.

PubMed CentralRead more →

Stage IIIB HER2-positive breast cancer followed by resected pancreatic ductal adenocarcinoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Breast cancer HER2-amplified; ER/PR changed from positive to negative after treatment. Pancreatic markers supported a separate pancreatic cancer.

The breast cancer achieved radiological and clinical remission after multimodality HER2-directed treatment. In 2025, a separate pancreatic ductal adenocarcinoma was resected, and adjuvant gemcitabine plus albumin-bound paclitaxel was recommended.

PubMed CentralRead more →

Stage IIIC ER-positive male breast cancer: mastectomy, chemotherapy, radiation, tamoxifen and abemaciclib

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: ER 90% positive; PR 60% positive; HER2 score 0; Ki-67 15%; BRCA1 and BRCA2 no pathogenic variants; CEA 2.4 ng/mL; CA15-3 13.6 U/mL

He remained on tamoxifen and dose-adjusted abemaciclib; annual follow-up imaging, including non-contrast CT, showed no local or distant relapse.

PubMed CentralRead more →